News | February 09, 2015

ISET Discusses Minimally Invasive Clip to Repair Mitral Valve Regurgitation

Approximately one-third of patients who have the procedure need more than one clip to correct the problem

Heart failure, MitraClip, International Symposium on Endovascular Therapy

Image courtesy of Abbott Vascular

February 9, 2015 — A minimally invasive procedure to repair severe mitral valve regurgitation by clipping together the valve’s leaflets can improve function and quality of life and reduce the risk of hospitalization, research shows. Approximately one-third of patients who have the procedure need more than one clip to correct the problem, suggest data presented at the 27th annual International Symposium on Endovascular Therapy (ISET).

Mitral valve prolapse is a common condition in which the valve’s leaflets do not close properly. Many people with the condition never have symptoms, but in severe cases the blood leaks backward into the left atrium of the heart. About 250,000 people a year are diagnosed with this condition, called mitral valve regurgitation, which can cause shortness of breath, dizziness, fatigue and an irregular heartbeat. Recently approved by the U.S. Food and Drug Administration (FDA), the MitraClip holds together the valve’s leaflets to reduce the degree of regurgitation.

“In many cases one clip is sufficient; however in one-third of the patients additional clips are necessary to reduce the degree of regurgitation without producing stenosis, making the valve too tight,” said Ramon Quesada, M.D., medical director of Interventional Cardiology & Cardiac Research for the Miami Cardiovascular Institute.

Quesada was an investigator in the EVEREST II trial, which enrolled 279 patients with severe mitral valve disease. Patients were randomized to either undergo surgical repair (95 patients) or to have the clip placed (184 patients). In the subgroup of patients who were at high risk for surgical repair it was found that the Mitraclip procedure was beneficial because it improved the patient’s cardiovascular function and reduced the rate of hospitalization for heart failure.

Mitral valve regurgitation (also called mitral valve prolapse) is the most common type of heart valve problem in the United States. Every year, about 50,000 people have a severe enough problem that they require surgery, which is the “gold standard” treatment. However, open-heart surgical valve repair is a major procedure requiring heart-lung bypass and prolonged anesthesia. The valve is then replaced or repaired using a variety of techniques. Because many of these patients are older, surgery is often considered too high risk. In the non-surgical transcatheter treatment with MitraClip, the physician threads a catheter through the arteries and advances a clothespin-like clip into the heart’s left atrium where it is positioned to clasp the leaflets together, allowing blood to continue flowing but not back up into the atrium. The device is made of metal and covered with a polyester fabric.

For more information: www.iset.org

 

 

Related Content

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
Overlay Init